COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS
UNIVERSITÈ D'AIX-MARSEILLE;ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (AFM);ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE;UNIVERSIDAD DE OVIEDO
发明人:
Nicolas LEVY,Pierre CAU,Carlos LOPEZ-OTIN
申请号：
US14575814
公开号：
US20150105352A1
申请日:
2014.12.18
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
